Source item
Open original source ↗What a breath of fresh air at the FDA! According to @NMDespotARK, health care analysts and investors are likely to be stunned by the pace of deregulation and and innovation at the FDA...which already has lessened the need for certain animal testing and randomized control studies.
Quoted context
These are the quoted author’s words.
FDA Commissioner Makary sits down for a conversation with the newly appointed director of the Center for Biologics Evaluation and Research (CBER) Dr. Vinayak “Vinay” Kashyap Prasad and Sanjula Jain-Nagpal, Associate Director of Policy & Research Strategy, Office of the Commissioner (OC). The trio talks about the current and future happenings at the FDA.
FDA ↗